Overview

LEAP-CT for Treatment of COVID-19 Patients (Master Protocol)

Status:
Not yet recruiting
Trial end date:
2022-11-01
Target enrollment:
Participant gender:
Summary
This master protocol serves as a common reference for the inpatient and outpatient clinical studies that share common elements.
Phase:
Phase 2
Details
Lead Sponsor:
Leidos Life Sciences
Collaborator:
United States Department of Defense
Treatments:
Celecoxib
Famotidine